Dr Reddys Laboratories (RDY) Notes Payables (2012 - 2026)

Dr Reddys Laboratories' Notes Payables history runs 14 years deep, the most recent figure standing at $646.9 million for Q1 2026.

• In Q1 2026, Notes Payables rose 47.24% year-over-year to $646.9 million; the TTM figure through Mar 2026 stood at $646.9 million (up 47.24% YoY), while the FY2026 annual figure was $630.0 million, up 41.57% from the prior year.
• Notes Payables was $646.9 million for Q1 2026 at Dr Reddys Laboratories, up from $471.8 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $646.9 million in Q1 2026 to a low of $70.7 million in Q3 2023.
• Historically, Notes Payables has averaged $292.3 million across 5 years, with a median of $256.7 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Notes Payables tumbled 75.04% in 2023, then jumped 574.79% in 2024.
• A 5-year view of Notes Payables shows it stood at $135.1 million in 2022, then sank by 47.64% to $70.7 million in 2023, then surged by 574.79% to $477.3 million in 2024, then decreased by 1.14% to $471.8 million in 2025, then surged by 37.1% to $646.9 million in 2026.
• The last three Notes Payables figures came in at $646.9 million (Q1 2026), $471.8 million (Q3 2025), and $439.3 million (Q1 2025), per Business Quant data.